| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 3770.6 | 3900.6 | 3256.2 |
| Other income | 189.1 | 44.5 | 11.7 |
| Total income | 3959.7 | 3945.1 | 3267.9 |
| Profit before exceptional items & tax | 761.2 | 718.3 | 380.8 |
| Exceptional items | 373.4 | 184.3 | 372.8 |
| Profit before tax | 387.8 | 534.0 | 8.0 |
| Net profit | 301.3 | 403.2 | 4.4 |
| Operating margin | 9.8% | 13.5% | 0.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6747.70% |
|---|---|
| Net profit, quarter on quarter | -25.30% |
| Revenue, year on year | +15.80% |
BSE results filing, NSE: GLENMARK. Figures extracted from the filing.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,380.00
- Market cap
- ₹67,169 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 37.4×Sector 50.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).
- Call
- Guides 15% growth
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.
- Call
- Guides 15% growth